CP and lung carcinoma: Non-small-cell lung cancer (NSCLC) represents a heterogeneous group of tumors that account for >85% of the newly diagnosed lung cancer incidents.1 Multiple approaches have been applied for the treatment of NSCLC, among which are the apoptosis-induction chemotherapy agents such as cisplatin (CP).1, 2 But unfortunately, considerably high rate of relapse occurs following CP treatment despite the approaches aiming to overcome resistance.3, 4, 5 It is thus necessary to develop strategies that act on the CP-resistant subpopulation of NSCLC and reverse the resistance in these tumor cells.